RecruitingPhase 2 / Phase 3NCT05485961
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
Sponsor: CSL Behring
Albany, NY · Brooklyn, NY · College Point, NY · +164 more sites